REFERENCES
- Walensky RP, Paltiel AD, Losina E, et al. The survival ben-efits of AIDS treatment in the United States. J Infect Dis. 2006;194(1):11–19.
- Chesney MA, Ickovics J, Hecht FM, Sikipa G, Rabkin J. Adherence: A necessity for successful HIV combination therapy. AIDS. 1999;13(Suppl A):S271–278.
- Reynolds NR. Adherence to antiretroviral therapies: State of the science. Curr HIV Res. 2004;2(3):207–214.
- Paterson DL, Swindells S, Mohr J, et al. Adherence to pro-tease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30.
- Bangsberg DR. Less than 95% adherence to nonnucleo-side reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43(7):939–941.
- Simoni JM, Pearson CR, Pantalone DW, Marks G, Crepaz N. Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load. A meta-analytic review of randomized controlled trials. J Acquir Immune Defic Syndr. 2006;43(Suppl 1): S23–35.
- Bangsberg DR, Perry S, Charlebois ED, et al. Non-adher-ence to highly active antiretroviral therapy predicts pro-gression to AIDS. AIDS. 2001;15(9):1181–1183.
- Garcia de OlaIla P, Knobel H, Carmona A, Guelar A, Lopez-Colomes JL, Cayla JA. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr. 2002;30(1):105–110.
- Hogg RS, Heath K, Bangsberg D, et al. Intermittent use of triple-combination therapy is predictive of mor-tality at baseline and after 1 year of follow-up. AIDS. 2002;16(7)1 051–1058.
- Hogg RS, Bangsberg DR, Lima VD, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med. 2006;3(9):e356.
- Chesney MA, Morin M, Sherr L. Adherence to HIV combi-nation therapy. Soc Sc/Med. 2000;50(11):1599–1605.
- Heckman BD, Catz SL, Heckman TG, Miller JG, Kalichman SC. Adherence to antiretroviral therapy in rural persons living with HIV disease in the united states. AIDS Care. 2004;16(2):219–230.
- Simoni JM, Frick PA, Pantalone DW, Turner BJ. Antiretro-viral adherence interventions: A review of current literature and ongoing studies. Top HIV Med. 2003;11(6):185–198.
- Simoni JM, Amico KR, Pearson CR, Malow R. Strategies for promoting adherence to antiretroviral therapy: A review of the literature. Curr Infect Dis Rep. 2008;10(6):515–521.
- Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Mer-rill JO, Frick PA. Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management. AIDS Behav. 2006;10(3):227–245.
- Simoni JM, Amico KR, Smith L, Nelson K. Antiretroviral adherence interventions: Translating research findings to the real world clinic. Curr HIV/AIDS Rep. 2010;7(1):44–51.
- Collier AC, Ribaudo H, Mukherjee AL, et al. A random-ized study of serial telephone call support to increase adherence and thereby improve virologic outcome in persons initiating antiretroviral therapy. J Infect Dis. 2005;192(8):1398–1406.
- Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003;349(24):2293–2303.
- Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J. Med. 2003;349(24):2304–2315.
- Reynolds NR, Testa MA, Su M, et al. Telephone support to improve antiretroviral medication adherence: A multisite, randomized controlled trial. J Acquir Immune Defic Syndr. 2008;47(1):62–68.
- Safren SA, Otto MW, Worth JL, et al. Two strategies to increase adherence to HIV antiretroviral medication: Life-steps and medication monitoring. Behav Res Ther. 2001;39(10):1151–1162.
- Safren SA, Otto MW, Worth JL. Life-steps: Applying cog-nitive behavioral therapy to HIV medication adherence. Cogn Behav Pract. 1999 ;6(4):332–341.
- Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG adherence instruments. Patient Care Committee & Adherence Work-ing Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care. 2000;12(3):255–266.
- Reynolds NR, Sun J, Nagaraja HN, Gifford AL, Wu AW, Chesney MA. Optimizing measurement of self-reported adherence with the ACTG adherence questionnaire: A cross-protocol analysis. J Acquir Immune Defic Syndr. 2007;46(4):402–409.
- Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: A meta-analysis. JAMA. 2006;296(6):679–690.
- Gardner EM, Sharma S, Peng G, et al. Differential adher-ence to combination antiretroviral therapy is associ-ated with virological failure with resistance. AIDS. 2008;22(1):75–82.
- Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–497.
- Amico KR, Zuniga JM, Wilson IB, Gross R, Young B. Pro-vider guidance for linking patients to antiretroviral therapy adherence interventions: Recommendations from an IAPAC advisory committee on adherence monitoring and support. J Int Assoc Provid AIDS Care. 2013;12(2):79–83.
- Lu M, Safren SA, Skolnik PR, et al. Optimal recall period and response task for self-reported HIV medication adher-ence. AIDS Behav. 2008;12(1):86–94.
- de Bruin M, Viechtbauer W, Schaalma HP, Kok G, Abraham C, Hospers HJ. Standard care impact on effects of highly active antiretroviral therapy adherence interventions: A meta-analysis of randomized controlled trials. Arch Intern Med. 2010;170(3):240–250.